Rafael Holdings Inc (N:RFL)

Sector:  N/A Industry:  N/A
 
See Regulatory Filings on SEC
Company Contact
Address: 520 Broad St
NEWARK NJ 07120
Tel: N/A
Website: https://rafaelholdings.com
IR: See website
<
Key People
Howard S. Jonas
Executive Chairman of the Board
William Conkling
President, Chief Executive Officer
David A. Polinsky
Chief Financial Officer
John M. Goldberg
Chief Medical Officer
   
Business Overview
Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies. The Company's segments include healthcare and real estate. The Company's investments include Cornerstone Pharmaceuticals, Inc., which is a cancer metabolism-based therapeutics company; LipoMedix Pharmaceuticals Ltd., which is a clinical-stage pharmaceutical company; Barer Institute Inc., which is a preclinical cancer metabolism research operation; Cyclo Therapeutics Inc., which is a clinical-stage biotechnology company dedicated to developing medicines for patients and families living with diseases through its therapeutic asset like Trappsol and Cyclo; Day Three Labs, Inc., which offers pharmaceutical-grade technology like Unlokt, and Rafael Medical Devices, LLC, which is an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries. Its real estate segment comprises of a portion of a commercial building in Israel.
Financial Overview
For the six months ended 31 January 2024, Rafael Holdings Inc revenues decreased 3% to $136K. Net income before extraordinary items totaled $2.4M vs. loss of $8.2M. Revenues reflect Rental - Third Party decrease of 5% to $82K. Net Income reflects Healthcare segment loss decrease of 40% to $5.6M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.36 to $0.10.
Employees: 13 as of Oct 30, 2023
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $0.28M as of Jan 31, 2024
EBITDA (TTM): -$11.17M as of Jan 31, 2024
Net annual income (TTM): $2.26M as of Jan 31, 2024
Free cash flow (TTM): -$7.42M as of Jan 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 24,584,439 as of Mar 11, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.